Related references
Note: Only part of the references are listed.Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application
V. Taucher et al.
CELLULAR ONCOLOGY (2016)
Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9
Irene Amigo-Jimenez et al.
ONCOTARGET (2016)
Deregulation of polycomb repressor complex 1 modifier AUTS2 in T-cell leukemia
Stefan Nagel et al.
ONCOTARGET (2016)
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Alessio Amatu et al.
ESMO OPEN (2016)
Malat1 as an evolutionarily conserved lncRNA, plays a positive role in regulating proliferation and maintaining undifferentiated status of early-stage hematopoietic cells
Xian-Yong Ma et al.
BMC GENOMICS (2015)
Predicting genetic interactions from Boolean models of biological networks
Laurence Calzone et al.
INTEGRATIVE BIOLOGY (2015)
Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines
Haiping Dai et al.
PLOS ONE (2015)
Long non-coding RNAs in cancer: implications for personalized therapy
Marianna Vitiello et al.
CELLULAR ONCOLOGY (2015)
The Long Noncoding RNAs NEAT1 and MALAT1 Bind Active Chromatin Sites
Jason A. West et al.
MOLECULAR CELL (2014)
Cancer Cytogenetics: Methodology Revisited
Thomas S. K. Wan
ANNALS OF LABORATORY MEDICINE (2014)
TrkC promotes survival and growth of leukemia cells through Akt-mTOR-Dependent Up-Regulation of PLK-1 and Twist-1
Min Soo Kim et al.
MOLECULES AND CELLS (2013)
Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia
Johanna M. Kralik et al.
DIAGNOSTIC PATHOLOGY (2011)
Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH2 Terminal Kinase Activation and PTEN Upregulation
Javier Redondo-Munoz et al.
CLINICAL CANCER RESEARCH (2010)
Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
Kenneth Thress et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Cytogenetic harvesting of commonly used tumor cell lines
Roderick A. F. MacLeod et al.
NATURE PROTOCOLS (2007)
Phosphoproteomic analysis identifies the M0-91 cell line as a cellular model for the study of TEL-TRKC fusion-associated leukemia
T-L Gu et al.
LEUKEMIA (2007)
ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages
CL Lannon et al.
SEMINARS IN CANCER BIOLOGY (2005)
Directing oncogenic fusion genes into stem cells via an SCL enhancer
M Eguchi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide
Y Sun et al.
LEUKEMIA (2004)
Steady-state analysis of genetic regulatory networks modelled by probabilistic Boolean networks
I Shmulevich et al.
COMPARATIVE AND FUNCTIONAL GENOMICS (2003)
Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression
CA Kim et al.
EMBO JOURNAL (2001)
Neurotrophin signal transduction in the nervous system
DR Kaplan et al.
CURRENT OPINION IN NEUROBIOLOGY (2000)
The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells
DH Wai et al.
ONCOGENE (2000)
Share Paper
